Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA by Karikó, Katalin et al.
Generating the optimal mRNA for therapy:
HPLC purification eliminates immune activation
and improves translation of nucleoside-modified,
protein-encoding mRNA
Katalin Kariko ´
1, Hiromi Muramatsu
1,J a ´nos Ludwig
2 and Drew Weissman
3,*
1Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA,
2Institute of Clinical Chemistry
and Pharmacology, University of Bonn, Bonn, Germany and
3Department of Medicine, University of
Pennsylvania, Philadelphia, PA, USA
Received May 26, 2011; Revised August 9, 2011; Accepted August 10, 2011
ABSTRACT
In vitro-transcribed mRNA has great therapeutic po-
tential to transiently express the encoded protein
without the adverse effects of viral and DNA-based
constructs. Mammalian cells, however, contain RNA
sensors of the innate immune system that must
be considered in the generation of therapeutic
RNA. Incorporation of modified nucleosides both
reduces innate immune activation and increases
translation of mRNA, but residual induction of
type I interferons (IFNs) and proinflammatory cyto-
kines remains. We identify that contaminants,
including double-stranded RNA, in nucleoside-
modified in vitro-transcribed RNA are responsible
for innate immune activation and their removal by
high performance liquid chromatography (HPLC)
results in mRNA that does not induce IFNs and in-
flammatory cytokines and is translated at 10- to
1000-fold greater levels in primary cells. Although
unmodified mRNAs were translated significantly
better following purification, they still induced
high levels of cytokine secretion. HPLC purified
nucleoside-modified mRNA is a powerful vector for
applications ranging from ex vivo stem cell gener-
ation to in vivo gene therapy.
INTRODUCTION
Our understanding of the importance of RNA in biologic-
al processes and the therapeutic potential has substantially
increased with the discovery of non-coding regulatory
RNAs. The use of mRNA has also expanded, including
the delivery of mRNA to generate induced pluripotent
stem (iPS) cells (1–3) and in vivo administration to
express therapeutic proteins (4). The recognition that the
immunogenicity of RNA could be reduced by the incorp-
oration of modiﬁed nucleosides with a concomitant
increase in translation (5), potentially allows efﬁcient ex-
pression of intra and extracellular proteins in vivo and ex
vivo without activation of innate immune pathways.
Unfortunately, modiﬁed nucleoside-containing RNA
transcribed by phage RNA polymerase transcription still
retains a low level of activation of such pathways (3,5–7).
The remaining activation of RNA sensors by nucleoside
modiﬁed RNA could be because the modiﬁcations do not
completely suppress the RNAs ability to activate sensors
or due to contaminants with structures that activate in the
presence of nucleoside modiﬁcation. It is well established
that RNA transcribed in vitro by phage polymerase
contains multiple contaminants, including short RNAs
produced by abortive initiation events (8) and double-
stranded(ds)RNAs generatedbyself-complementary 30 ex-
tension (9), RNA-primed transcription from RNA tem-
plates (10) and RNA-dependent RNA polymerase
activity (11).
Large quantities of RNA can be easily prepared by
in vitro transcription from DNA templates using phage
RNA polymerase or solid-phase chemical synthesis. For
uses that require further puriﬁcation, such as NMR (12),
crystallography (13) and therapeutic applications (14), a
number of techniques have been developed. Preparative
denaturing polyacrylamide gel electrophoresis is
commonly used to purify in vitro-transcribed RNA,
however, this method is suitable only for short RNAs
[reviewed in (15)]. Long RNAs can be separated on
denaturing agarose gels, but they are not translatable
due to covalent modiﬁcations introduced by the denatur-
ants glyoxal and formaldehyde (16). Chromatography
based on size exclusion can efﬁciently remove unincorpor-
ated nucleoside triphosphates, small abortive transcripts
and plasmid template from the desired RNA product
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to remove contaminants with similar sizes and contamin-
ants complementary to the RNA selected to purify. No
technique has been reported for puriﬁcation and prepara-
tive isolation of long in vitro-transcribed mRNA that
removes contaminating complementary strands and pre-
serves its translatability.
The development of mRNA to use as a tool to replace
intra- and extracellular proteins in vivo and to
transdifferentiate, reprogram and differentiate cells ex
vivo requires the RNA to have high translatability and
no RNA sensor activation. In this report, we identify
that contaminants from in vitro-transcribed RNA are a
source of innate immune activation and their removal in-
creases RNA translation and eliminates type I interferon
and inﬂammatory cytokine secretion.
MATERIALS AND METHODS
Cells
Human embryonic kidney 293T cells (American Type
Culture Collection) were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 2mM L-glu-
tamine (Life Technologies) and 10% fetal calf serum
(FCS) (HyClone) (complete medium). Human and
murine dendritic cells (DCs) were generated as described
(5). Human keratinocytes were obtained from the Skin
Disease Research Core (Penn) and grown in MCDB
with bovine pituitary extract (140mg/ml) (Sigma) and
70mMC a
+ + on collagen (0.01mg/ml) (Invitrogen)
coated plates.
mRNA synthesis
mRNAs were transcribed as previously described (5),
using linearized plasmids encoding ﬁreﬂy luciferase
(pT7TSLuc and pTEVLuc), codon-optimized murine
erythropoietin (pTEVmEPO), enhanced green ﬂuorescent
protein (pTEVeGFP), Metridia luciferase (pT7TSMetluc)
or Renilla luciferase (pT7TSRen and pTEVRen) and T7
RNA polymerase (Megascript, Ambion). All mRNAs were
transcribed to contain 30 or 51-nt long poly(A) tails.
Additional poly(A) tail was added with yeast poly(A) poly-
merase (USB) and noted as An. Triphosphate-derivatives of
pseudouridine () and 5-methylcytidine (m5C) (TriLink)
were used to generate modiﬁed nucleoside containing
RNA. All RNAs were capped using the m7G capping
kit with or without 20-O-methyltransferase (ScriptCap,
CellScript) to obtain cap1 or cap0. We did not observed
differences in the immunogenicity of cap0- and cap1-
containing nucleoside-modiﬁed RNAs. All RNAs were
analyzed by denaturing or native agarose gel electrophor-
esis. Pseudouridine-modiﬁed mRNAs encoding KLF4,
LIN28, cMYC, NANOG, OCT4 and SOX2 were a kind
gift of CellScript, Inc.
HPLC puriﬁcation of RNA
RNA was puriﬁed by High performance liquid
chromatography (HPLC) (Akta Puriﬁer, GE Healthcare)
using a column matrix of alkylated non-porous
polystyrene-divinylbenzene copolymer microspheres
(2.1mm) (21 100mm column). Buffer A contained
0.1M triethylammonium acetate (TEAA), pH=7.0 and
Buffer B contained 0.1M TEAA, pH=7.0 and 25%
acetonitrile (Transgenomics). Columns were equilibrated
with 38% Buffer B, loaded with RNA and run with a
single or 2 linear gradients to 55 or 65% Buffer B over
20–30min at 5ml/min. RNA analyses were performed
with the same column matrix and buffer system using a
7.8mm 50mm column at 1.0ml/min.
RNA isolation from column fractions
RNA content from desired fractions was concentrated and
desalted using Amicon Ultra-15 centrifugal ﬁlter units
(30K membrane) (Millipore) by successive centrifugation
at 4000g for 10min (4 C) in a Sorvall ST16R centrifuge
(Thermo Scientiﬁc) and dilution with nuclease free water.
The RNA was recovered by overnight precipitation at
 20 C in NaOAc (0.3M, pH 5.5), isopropanol
(1 volume) (Fisher) and glycogen (3ml) (Roche).
Dot blot
RNA (200ng) was blotted onto super charged Nytran,
dried, blocked with 5% non-fat dried milk in TBS-T
buffer (50mM Tris–HCl, 150mM NaCl, 0.05%
Tween-20, pH 7.4), and incubated with dsRNA-speciﬁc
mAb J2 or K1 (English & Scientiﬁc Consulting) for
60min. Membranes were washed six times with TBS-T
and reacted with HRP-conjugated donkey anti-mouse Ig
(Jackson Immunology), washed six times and detected
with ECL Plus Western blot detection reagent
(Amersham). Images were captured on a Fujiﬁlm
LAS1000 digital imaging system. dsRNA (25ng) used as
a positive control was derived from sense and antisense
strands of T7TS UTR sequence (328bp). Blots were
reprobed with
32P-labeled DNA complementary to the
30-UTR of the RNA to document the presence of RNA.
Complexing of RNA
Lipofectin (Invitrogen) complexing was performed as
described previously (5) using 0.8ml of Lipofectin and
0.1mg of RNA per well of a 96-well plate. Complexing
of RNA to TransIT mRNA (Mirus Bio) was performed
according to the manufacturer combining RNA (0.1mg)
with TransIT mRNA (0.3ml) and boost (0.2ml) reagents.
Cell transfections
For Lipofectin complexed RNA, medium was removed
and 50ml of complexed RNA was added to 5 x 10
4 293T
or DCs per well. Cells were incubated for 1h and the
Lipofectin-RNA mixture was replaced with 200ml
complete medium. For TransIT complexed RNA, 17ml
of complex was added to cells, 293T, DCs, or 2 10
5 kera-
tinocytes cultured in 183ml complete medium. Cells were
lysed in ﬁreﬂy or Renilla speciﬁc lysis reagents (Promega)
at 24h post RNA addition. Aliquots were assayed for
enzyme activities using ﬁreﬂy and Renilla luciferase
assay systems (Promega) and a LUMAT LB 950
luminometer (Berthold/EG&G; Wallac). Expression of
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epiﬂuorescent Nikon microscope mounted with a Nikon
D40 digital camera. Murine EPO protein was measured
with a speciﬁc ELISA assay (R&D Systems).
RNA immunogenicity analyses
DCs (murine or human) (5 10
4 cells/well) in 96-well
plates were treated with medium, R-848 (Invivogen), or
Lipofectin- or TransIT-complexed RNA or poly(I:C)
(Sigma). Supernatant was harvested after 24h and the
levels of IFN-a, IFN-b (PBL InterferonSource), or
TNF-a (Biosource International) were measured by
ELISA.
Gene array analysis
Human DCs from three donors were generated in 5%
FCS. Cells (1 10
6 DCs/well of a 6-well plate) were
treated with TransIT-complexed TEVRenA51 RNA with
or without modiﬁcation and with or without puriﬁcation.
Six hours later, RNA was isolated using RNeasy (Qiagen).
RNA was ampliﬁed with the TargetAmp Nano-g
Biotin-aRNA labeling kit (Epicentre) and analyzed on
an Illumina Human HT12v4 chip in an Illumina
BeadStation 500GX. Raw data was processed by the
Bead Studio v.3.0 software. Levels in untreated DC were
used as the baseline for the calculation of fold increase.
Northern blot
Samples were processed and analyzed as previously
described (6). Probes were derived from plasmids and
were speciﬁc for the coding regions of human IFN-a13,
IFN-b (Open Biosystems), TNF-a, or GAPDH (ATCC).
RESULTS
A dot blot assay with J2 and K1 monoclonal antibodies
(mAbs) that recognize dsRNA (19) was used to determine
whether in vitro-transcribed RNA contains dsRNA. These
mAbs recognize continuous double stranded structure
of at least 40bp in length (20), which is not found in
any of the coding sequences or UTRs in the mRNAs
analyzed in this study. Testing mammalian and re-
porter protein-encoding in vitro transcripts containing
either no nucleoside modiﬁcations, pseudouridine- (),
or 5-methylcytidine- (m5C) and - (m5C/) nucleoside
modiﬁcations, we found that all samples contained
dsRNA contamination (Figure 1A and data not shown).
Recognition of dsRNA by J2 mAb was not affected by the
presence of modiﬁed nucleosides, while K1 had reduced
binding to dsRNA containing  or m5C/ nucleoside
modiﬁcations.
Others and we have previously demonstrated that in-
corporation of modiﬁed nucleotides into RNA reduced
its ability to activate RNA sensors including Toll-like
receptor (TLR)3, TLR7 and TLR8 (21), retinoic acid
inducible gene I (RIG-I) (22) and RNA-dependent
protein kinase (PKR) (6,23). Monocyte-derived DCs
that express these and all other known RNA sensors
(24) were used to measure residual immune activation
present in modiﬁed nucleoside-containing RNA. A series
of RNAs with coding sequences for mammalian and
reporter proteins ﬂanked by different 50- and 30-UTRs
were analyzed. The RNAs were cell-delivered following
complexing with Lipofectin, a cationic lipid, or TransIT,
a membrane active polymer and lipid mixture. RNA com-
plexed with Lipofectin induced high levels of TNF-a and
moderate levels of IFN-a, while RNA complexed with
Figure 1. In vitro-transcribed RNA is immunogenic and contains
dsRNA contaminants. (A) 200ng of in vitro transcripts encoding
mEPO and containing the indicated modiﬁed nucleosides were
blotted and analyzed with K1 and J2 dsRNA-speciﬁc mAbs. The
dsRNA positive control contained a 328bp long dsRNA (25ng).
(B) DCs were treated with Lipofectin-complexed Renilla luciferase
(T7TSRenA30), ﬁreﬂy and Metridia luciferases (T7TSLucA30,
T7TSMetlucA30), and mEPO (TEVmEPOA51) mRNAs. TNF-a levels
were measured in the supernatants at 24h. (C) DCs were treated with
TransIT-complexed in vitro transcripts encoding Renilla and ﬁreﬂy
luciferases (T7TSRenA30, T7TSLucA30), eGFP (TEVeGFPA51) and
mEPO (TEVmEPOA51). IFN-a levels were measured in the super-
natants at 24h. Error bars are standard error of the mean. Data
shown is from one experiment that is representative of 3–6.
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IFN-a (data not shown) with some donor-dependent vari-
ation. Typically, Lipofectin-complexed RNA with  or
m5C/ modiﬁcations induced less TNF-a. (Figure 1B),
while TransIT-complexed RNA with or without nucleo-
side modiﬁcation induced variable, sequence-dependent
effects on IFN-a secretion (Figure 1C). These data
suggest that the presence of dsRNA and potentially
other contaminants in in vitro-transcribed RNA could be
responsible for innate immune activation.
Multiple HPLC bead matrix compositions and buffer
systems were screened and alkylated non-porous
polystyrene-divinylbenzene copolymer matrix and
triethylammonium acetate buffer with an acetonitrile
gradient was identiﬁed as a system capable of removing
dsRNA and other contaminants from in vitro-transcribed
RNA. The HPLC chromatogram of -modiﬁed mRNA
encoding enhanced green ﬂuorescent protein (eGFP)
demonstrated a major peak (Figure 2), which was col-
lected and identiﬁed as the expected RNA product using
agarose gel electrophoresis. Additional UV-absorbing
products with shorter and longer retention times relative
to the main RNA product could also be observed.
Reanalysis of the puriﬁed RNA by HPLC demonstrated
a single peak with the same retention time. RNAs with or
without nucleoside modiﬁcation encoding different se-
quences yielded similar patterns with varying relative
heights for the preceding and succeeding peaks.
HPLC puriﬁcation of both unmodiﬁed and nucleoside-
modiﬁed RNA reduced staining by dsRNA-speciﬁc mAb
to baseline levels (Figure 3A). Analysis of -modiﬁed
RNA encoding clinically relevant proteins demonstrated
that the amounts of dsRNA contamination in the in vitro
transcripts were dependent on the sequence, but HPLC
could successfully remove the contaminants from all of
them (Figure 3B). Next, the HPLC-puriﬁed RNAs were
tested on human DCs. No TNF-a or type-I interferons
(IFN-a and b) were induced following transfection of
HPLC-puriﬁed - or m5C/-modiﬁed RNAs that were
complexed with Lipofectin or TransIT, respectively
(Figure 3C and D and data not shown). Similarly, no
cytokine induction could be detected when HPLC-
puriﬁed modiﬁed nucleoside-containing RNAs were trans-
fected into murine DCs. HPLC puriﬁcation similarly
ablated IFN-a secretion from DCs transfected with the
clinically relevant -nucleoside modiﬁed mRNAs com-
plexed to TransIT used in Figure 3B. However,
HPLC-puriﬁed RNA without nucleoside modiﬁcation
remained potent inducers of TNF-a and IFN-a
(Figure 3C and D).
The impact of HPLC puriﬁcation of unmodiﬁed, - and
m5C/-modiﬁed RNA on gene expression in human DCs
was analyzed using gene arrays. Total cellular RNA
isolated from DCs from three different donors 6h after
cells were transfected with TransIT-complexed RNA, were
analyzed on an Illumina Human HT12v4 chip. RNA
modiﬁed with  or m5C/ nucleosides induced less ex-
pression of type I interferons, interleukins, tumor necrosis
factor (TNF) family members, chemokines and markers
associated with DC activation, while HPLC puriﬁcation
of - and m5C/-modiﬁed RNA further reduced induc-
tion of these genes to the levels observed in cells treated
only with TransIT (Figure 4A). The same sets of total
RNA from DCs that were tested on the gene arrays
were also analyzed for levels of IFN-a, IFN-b and
TNF-a mRNA by northern blot. Lower levels of IFN-a,
IFN-b and TNF-a mRNAs were detectable in DCs
treated with nucleoside modiﬁed as compared to unmodi-
ﬁed RNA. More importantly, none of these cytokine
mRNAs were detectable when DCs were transfected
with HPLC-puriﬁed RNAs containing  or m5C/ modi-
ﬁcation. However, HPLC puriﬁed RNA without nucleo-
side modiﬁcation remained a potent inducer of IFN-a,
IFN-b and TNF-a mRNAs (Figure 4B).
To determine whether HPLC puriﬁcation affected
translatability of in vitro transcripts, a series of mRNAs
were tested following cell delivery. HPLC-puriﬁed Renilla
and mouse erythropoietin (mEPO) mRNAs were
translated at 2- to 20-fold higher levels compared to un-
puriﬁed RNA when delivered to 293T cells by TransIT
(Figure 5A). In primary human DCs, the translational
enhancement was more robust, resulting in up to a
1000-fold increase when the same sets of unpuriﬁed and
HPLC-puriﬁed mRNAs were transfected with Lipofectin
(Figure 5B) or TransIT (Figure 5C). Similar increases in
translation were observed for other mRNAs after HPLC
puriﬁcation, including mRNAs encoding ﬁreﬂy luciferase,
human EPO, macaque EPO and Metridia luciferase, and
other cell types, including mouse embryonic ﬁbroblasts
and human primary keratinocytes. Translation levels
were much higher with - and m5C/-modiﬁed eGFP
mRNA when the mRNA was HPLC-puriﬁed prior to
transfection of human DCs (Figure 5D and data not
shown).
To characterize the contaminants being removed by
HPLC puriﬁcation, three fractions corresponding to RNAs
eluting from the column prior to the major transcription
product (fraction I), the full-length transcription product
(fraction II), and RNAs eluting after the
Figure 2. HPLC puriﬁcation of RNA identiﬁes contaminants eluting
before and after the expected product. Chromatogram of -modiﬁed
TEVeGFPAn mRNA. RNA was applied to the HPLC column and
eluted using a linear gradient of Buffer B (0.1M TEAA, pH 7.0,
25% acetonitrile) in Buffer A (0.1M TEAA, pH 7.0). The gradient
spanned 38–55% Buffer B over 22min (red line). Absorbance at
260nm was analyzed (black line), which demonstrated the expected
sized RNA as well as smaller and larger RNA species. Data shown
are from one experiment that is representative of over 200.
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lected (Figure 6A). Nucleoside-modiﬁed RNA occasional-
ly demonstrated a second smaller peak overlying the large
peak and isolation and puriﬁcation of both peaks
demonstrated similar RNA lengths on denaturing and
non-denaturing agarose gel electrophoresis and RNAs
with similar levels of translation and immunogenicity.
RNA puriﬁed from the three fractions was analyzed for
immunogenicity. RNA in fractions I and III induced
IFN-a secretion from transfected DCs, while the puriﬁed
full-length RNA (fraction II) was not immunogenic when
it contained - or m5C/-nucleoside modiﬁcations
(Figure 6B). Fraction I RNA had low levels of staining
with the J2 mAb, while fraction III RNA had high levels
of staining similar to the unpuriﬁed RNA (Figure 6C).
Primary human keratinocytes and murine ﬁbroblasts
treated once with unpuriﬁed, unmodiﬁed RNA delivered
by TransIT complexing demonstrated detachment from
the collagen-coated plastic base as evidence of cell death.
A second delivery of unmodiﬁed RNA 24h later resulted
in the termination of the culture. Substantially less tox-
icity was observed when the RNA contained - or m5C/
-nucleoside modiﬁcations, but repeated daily delivery
of m5C/-nucleoside modiﬁed mRNA to keratino-
cytes reduced the ﬁnal cell number by 75% on day 11
(Figure 7). HPLC puriﬁcation of the RNA greatly
reduced toxicity in treated keratinocytes where unmodi-
ﬁed mRNA caused minimal cell rounding and death.
Daily treatment of keratinocytes for 10 days with
HPLC-puriﬁed m5C/-modiﬁed mRNA complexed to
TransIT showed no signs of cell toxicity and the rate of
proliferation was similar to that obtained with TransIT
alone treated cells (Figure 7).
DISCUSSION
Modiﬁed nucleoside-containing mRNA has previously
been used for the induction of iPS cells from ﬁbroblasts
with very high efﬁciency (3). The authors determined that
m5C/-nucleoside modiﬁed mRNA yielded the least
amount of RNA sensor activation and the highest level
of translation, but needed to add the B18R protein, a
vaccinia virus decoy receptor for type I interferon (25),
for optimal iPS cell generation. We previously reported
that modiﬁed nucleoside-containing mRNA was efﬁcient-
ly delivered to primary dividing and non-dividing cells and
produced high levels of encoded protein in an easily
controlled manner (5). In addition, the RNA had
reduced innate immune sensor activation. The residual
amount of activation of modiﬁed nucleoside-containing
Figure 3. HPLC puriﬁcation of in vitro-transcribed nucleoside modiﬁed mRNA removes dsRNA contaminants and eliminates immunogenicity.
(A) 200ng of RNA encoding the indicated protein and containing the indicated modiﬁed nucleosides with or without HPLC puriﬁcation were
blotted and analyzed with the J2 dsRNA-speciﬁc mAb. (B) 200ng of RNA encoding the indicated protein and containing -modiﬁcations with or
without HPLC puriﬁcation were blotted and analyzed with the J2 dsRNA-speciﬁc mAb. Blots were reprobed with a
32P-labeled probe for the
30-UTR of the RNAs to control for amount of RNA analyzed. (C) DCs were treated with TEVRenA51 RNA containing the indicated nucleoside
modiﬁcations with or without HPLC puriﬁcation and complexed to Lipofectin. TNF-a levels were measured in the supernatants at 24h. Differences
in the effect of nucleoside modiﬁcation on immunogenicity of Renilla-encoding mRNA compared to Figure 1B is likely due to donor variation and
differences in UTRs of the RNAs. (D) DCs were treated with TEVLucA51 RNA containing the indicated nucleoside modiﬁcations with or without
HPLC puriﬁcation and complexed to TransIT. IFN-a levels were measured in the supernatants at 24h. Error bars are standard error of the mean.
Data shown is from one experiment that is representative of 3 or more.
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identify that m5C/-nucleoside-modiﬁed RNA often has
the least ability to induce RNA sensor activation, but even
with these modiﬁcations, certain RNA sequences induce
high levels of cytokine production (Figure 1B and C).
HPLC puriﬁcation removes dsRNA and other contamin-
ants from in vitro-transcribed RNAs containing  or
m5C/ nucleosides, yielding RNA with the highest
levels of translation, up to 1000-fold more than
non-HPLC puriﬁed RNA with no release of type I IFNs
or TNF-a and no signiﬁcant induction of genes associated
with RNA sensor activation. The puriﬁcation procedure
can be easily scaled to produce large amounts of RNA
necessary for therapeutic applications and can be
completed quickly and efﬁciently.
The data suggests that different types of immunogenic
contaminants are present in in vitro-transcribed mRNA. A
series of RNAs that eluted before the major transcription
product, suggesting a smaller size, induced high levels of
IFN-a, but had minimal staining with dsRNA-speciﬁc
Figure 4. HPLC puriﬁcation of in vitro-transcribed nucleoside-modiﬁed mRNA eliminates activation of genes associated with RNA sensor activa-
tion. (A) Heatmap representing changes in expression of genes activated by RNA sensors were derived from microarray analyses of DCs treated for 6
hr with TransIT alone or transit-complexed TEVRenA51 RNA with the indicated modiﬁcations with or without HPLC puriﬁcation. RNA from
medium-treated cells was used as the baseline for comparison. (B) Northern blot of RNA from DCs treated with medium or TransIT alone or
TransIT-complexed TEVRenA51 RNA with the indicated modiﬁcations with or without HPLC puriﬁcation and probed for IFN-a, IFN-b, TNF-a
and GAPDH mRNAs.
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transcription product were immunogenic when the RNA
was unmodiﬁed or contained -modiﬁcations and had
levels of dsRNA staining similar to the unpuriﬁed RNA
(Figure 6). Long RNA (2kb) with an added shorter length
(276nt) of complimentary RNA eluted at high concentra-
tions of acetonitrile, i.e. had a longer retention time, sug-
gesting that ds structures delay elution from the column
matrix (K.K., H.M. and D.W., preliminary data). Three
of the known mechanisms that produce contaminants
during in vitro transcription, self-complementary 30 exten-
sion (9), RNA-primed transcription from RNA templates
(10) and RNA-dependent RNA polymerase activity (11)
can result in dsRNA of various lengths. If these contam-
inants contain the main transcription product, they would
likely elute after the main transcription product.
Interestingly, fraction III RNA from the puriﬁcation of
m5C/-modiﬁed RNA stained with dsRNA mAb, but
induced little IFN-a (Figure 6). dsRNA containing nu-
cleoside modiﬁcations, including , has reduced ability
to activate PKR (23), but whether m5C/-nucleoside
modiﬁcations in dsRNA block its ability to induce type
I IFNs through RNA sensors is unknown. The nature of
the contaminants that elute prior to the main product is
unknown. They have minimal staining with dsRNA
speciﬁc mAb, but these mAbs require extended lengths
of dsRNA for binding (20). We cannot rule out that
shorter segments of dsRNA are present in the RNA that
elutes prior to the main transcription product.
HPLC puriﬁcation of mRNAs enhanced their transla-
tion up to a 1000-fold in primary cells. The level of en-
hancement was greatest when the mRNA was unmodiﬁed,
decreased when  was incorporated and decreased fur-
ther when m5C and  were present (Figure 5A–C).
These differences in translational enhancement of the
mRNAs are likely due to the RNA sensors PKR and
oligoadenylate synthetase (OAS) that directly decrease
translation with activation. We previously demonstrated
that incorporation of m5C and  into long mRNA
reduced its ability to activate PKR (6). Similarly, we
Figure 5. HPLC puriﬁcation of in vitro transcribed mRNA enhances translation. 293T (A) and human DCs (B and C) were transfected with
TransIT- (A and C) or Lipofectin- (B) complexed TEVRenA51 or TEVmEPOA51 mRNA with the indicated modiﬁcations with or without
HPLC puriﬁcation and analyzed for Renilla luciferase activity or levels of supernatant-associated mEPO protein at 24h. (D) Human DCs were
transfected with -modiﬁed TEVeGFPAn mRNA with or without HPLC puriﬁcation (0.1mg/well) complexed with Lipofectin or TransIT and
analyzed 24h later. Error bars are standard error of the mean. Data shown is from one experiment that is representative of three or more.
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the absence of dsRNA contaminants induced less activa-
tion of OAS compared to unmodiﬁed mRNA (26). It is
also possible that RNA samples with nucleoside modiﬁca-
tions contain a smaller amount of short dsRNA contam-
inants as the dsRNA-speciﬁc mAbs do not recognize
dsRNA shorter than 40bp. An additional mechanism
for the inhibition of translation by mRNA containing
dsRNA contaminants could involve RNA interference.
dsRNA greater than 27bp in length is a substrate for
Dicer (27), whose action can lead to a speciﬁc suppression
of translation through the RNAi pathway (28). dsRNA
contaminants homologous to the desired mRNA would
lead to a speciﬁc suppression of translation in addition
to the non-speciﬁc suppression through RNA sensors of
the innate immune system.
The observation that the complexing agent used with
identical RNAs alters the type of cytokines released
from DCs could be caused by an effect of the complexing
agent on the interaction between the RNA and endosomal
RNA sensors, the location of RNA after cytoplasmic
entrance, or the amount of time the RNA remains in the
endosome after endocytosis. RNA sensing TLRs require
acidiﬁcation of endosomes to signal (29). A complexing
agent that allows endocytosed RNA to exit the
endosome and enter the cytoplasm before acidiﬁcation
and TLR signaling would result in reduced TNF-a secre-
tion, as was observed with TransIT-complexed mRNA. In
a comparison of cationic liposomes to linear
polyethyleneimine (PEI) (a cationic polymer) delivery of
CpG containing DNA, it was found that PEI-DNA
induced less TNF-a, which was associated with a faster
exit from endosomes, while cationic lipid delivery resulted
in DNA remaining in vesicular structures for extended
periods of time and high levels of TNF-a (30). We simi-
larly observed that cationic liposome complexed RNA
induced higher levels of TNF-a compared to the cationic
polymer with lipid TransIT. Another possibility for the
discrepant cytokine response could be due to the sizes of
the complexed mRNA particles. A recent report by
Retting et al. (31) demonstrated that nanometric particles
Figure 6. Analysis of RNA contaminants removed by HPLC puriﬁca-
tion. (A) One hundred microgram of -modiﬁed T7TSLucA30 RNA
was applied to the HPLC column and 3 fractions were collected, all
RNAs eluting before the main transcription product (I), the expected
RNA (II), and all RNAs eluting after the main transcription product
(III). The gradient began at 38% Buffer B and increased to 43% Buffer
B over 2.5min and then spanned 43–65% Buffer B over 22min.
Unmodiﬁed and m5C/-modiﬁed T7TSLucA30 RNA had similar frac-
tions obtained. (B) The RNAs from each fraction were complexed to
TransIT and added to DCs and IFN-a in the supernatant was
measured 24h later. Error bars are standard error of the mean.
(C) 200ng of RNA from the 3 fractions and the starting unpuriﬁed
RNA were blotted and analyzed with the J2 dsRNA-speciﬁc mAb.
Figure 7. Daily transfection with HPLC-puriﬁed m5C/-modiﬁed
mRNA does not reduce cell proliferation. Primary keratinocytes were
transfected daily with TransIT alone or m5C/-modiﬁed
RNA-encoding Renilla luciferase with or without HPLC puriﬁcation
complexed with TransIT. Every 2–3 days, cultures were split and equal
numbers of cells for each condition were plated. Total cell numbers for
each condition were divided by the total cell number in untreated cells
to calculate the percent of control proliferation.
e142 Nucleic Acids Research, 2011,Vol.39, No. 21 PAGE 8 OF 10induced IFN-a, while larger, micrometric particles
induced TNF-a even when the particles were made with
the same RNA and complexing agent.
Current gene therapy methods in clinical trials use viral
vectors that can activate innate immune sensors (32) and
integrate into host cell DNA (33) with potentially serious
complications. Although the use of mRNA for such
therapies seems a safer alternative, activation of RNA
sensors that alter cellular activities and impair the
intended function of the delivered mRNA (3) limit its use-
fulness. With the sequencing of the human genome and
the increasing ease and ability to sequence the genome of
individuals, new approaches are needed for the treatment
of inherited genetic disorders and therapies that require
in vivo expression of extracellular or intracellular
proteins. In addition, advances in regenerative medicine
therapies where transient expression of transcription
factors ex vivo transdifferentiate, reprogram and differen-
tiate cells are leading to new approaches for organ and
tissue restoration with the hope of treating many
diseases including diabetes, spinal cord injury, neurologic
syndromes and organ repair. As we report here, puriﬁca-
tion of modiﬁed nucleoside-containing mRNA avoids
RNA sensor activation and increases the translational
levels of the encoded protein. These mRNAs can be de-
livered repeatedly without toxicity or the need to add in-
hibitors of innate immune activation and can be used for
both ex vivo and in vivo therapies.
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